English  |  正體中文  |  简体中文  |  2828323  
???header.visitor??? :  32223600    ???header.onlineuser??? :  893
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"hsu c h"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 96-120 of 1656  (67 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-06-27T07:00:26Z Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; CHONG-JEN YU; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C.
臺大學術典藏 2022-06-27T07:00:25Z Influence of patient and provider factors on the workload of on-call physicians A general internal medicine cohort observational study Hsu N.-C.; Huang C.-C.; Jerng J.-S.; Hsu C.-H.; Yang M.-C.; Chang R.-E.; Ko W.-J.; CHONG-JEN YU
臺大學術典藏 2022-06-27T06:59:33Z Incidence of chronic thromboembolic pulmonary hypertension in Taiwan Liu H.-Y.; Lu T.-P.; Tao C.-W.; Wu Y.-J.; Huang W.-C.; Hsu C.-H.; Liao W.-C.; Hsu H.-H.; Lin M.-C.; CHONG-JEN YU
臺大學術典藏 2022-06-10T06:11:17Z Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:16Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏 2022-06-10T06:11:14Z The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:13Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Hsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:12Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:11Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:10Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y.; ZHONG-ZHE LIN; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:10Z Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma Shao Y.U.-Y.; Chen P.-J.; ZHONG-ZHE LIN; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:09Z Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:08Z Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:08Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2022-06-10T06:11:07Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:11:06Z Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:06Z A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏 2022-06-10T06:11:05Z Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:02Z Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2022-06-10T06:11:00Z Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.
臺大學術典藏 2022-06-10T06:10:59Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-06-10T06:10:58Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:56Z Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2022-06-10T06:10:55Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2022-06-10T06:10:54Z Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; ZHONG-ZHE LIN

Showing items 96-120 of 1656  (67 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page